Transplant Medicine

Dendritic cell manipulation can induce EBV-specific T cells to reduce PTLD risk

Published in Hepatitis Weekly, December 29th, 2003

Patient dendritic cells can be loaded with apoptotic/necrotic LCL to induce Epstein-Barr virus (EBV) specific T cells in EBV seronegative patients at risk for post-transplant lymphoproliferative disorders (PTLDs).

"PTLDs represent life-threatening complications of bone marrow and solid organ transplantation (SOTx). These are B-cell malignancies triggered by EBV infection in chronically immunosuppressed (IS) recipients," investigators in the United States report.

"Immunosuppressed EBV seronegative (EBV-) organ recipients are at highest risk of developing PTLD, owing to the lack of anti-EBV memory T cells to control subsequent EBV challenges. Our aim...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2003-12-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry